Related Experiment Video
Updated: Aug 5, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
TNFAIP3/A20 dysfunction drives innate and sterile hyperinflammation
Karel F A Van Damme1,2,3, Pieter Hertens4,5, Dorine Sichien1,2,6
1Laboratory of Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium.
Abstract:
Feedback mechanisms regulate immune activation and prevent excessive tissue damage. TNFAIP3, also known as A20, serves as a crucial brake on inflammation, and mutations or haploinsufficiency of this gene are linked to diseases characterized by inappropriate inflammation. In this study, we document highly conserved patterns of cell type-specific gene expression, regulation, and induction of TNFAIP3, and employ transgenic and gnotobiotic mouse models to investigate how adaptive immunity and the gut microbiome contribute to pathology arising from impaired A20 function. Contrary to our expectations, systemic inflammation resulting from Tnfaip3 deficiency in CD11c (Itgax)-expressing cells developed independently of autoreactive antibodies, B cells, and T cells. The microbiome also proved dispensable for disease manifestations in these models. These findings suggest that in diseases caused by insufficient TNFAIP3/A20 activity, autoantibodies may reflect a downstream consequence of disease rather than a causative driver, suggesting autoinflammatory rather than autoimmune pathology. These insights carry therapeutic implications for the treatment of TNFAIP3-associated diseases.
More Related Videos
09:51Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
09:24Functional Assessment of Intestinal Permeability and Neutrophil Transepithelial Migration in Mice using a Standardized Intestinal Loop Model
Published on: February 11, 2021
Related Concept Videos
Chronic Inflammation: Introduction
Inflammatory Bowel Disease III: Crohn's Disease
Acute Inflammation III: Local and Systemic Effects
Acute Inflammation I: Inflammatory Response
Inflammatory Bowel Disease II: Ulcerative Colitis
Acute Inflammation II: Cellular Phase